Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NP-G2-044 in advanced solid tumors
NCT03199586Phase 1Completed
- Sponsor
- Novita Pharmaceuticals
- Start
- Dec 2017
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Prilukae in solid tumor, sponsored by Novita Pharmaceuticals. Primary endpoint: Recommended Phase 2 Dose at 24 months. Started Dec 2017; status: completed.
02
Drugs
Prilukae
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03199586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03199586.